Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
38.73
+0.30 (0.77%)
Dec 19, 2025, 10:51 AM EST - Market open
Royalty Pharma Revenue
Royalty Pharma had revenue of $609.29M in the quarter ending September 30, 2025, with 7.90% growth. This brings the company's revenue in the last twelve months to $2.35B, up 3.70% year-over-year. In the year 2024, Royalty Pharma had annual revenue of $2.26B, down -3.86%.
Revenue (ttm)
$2.35B
Revenue Growth
+3.70%
P/S Ratio
7.10
Revenue / Employee
$23,735,798
Employees
99
Market Cap
22.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | 1.81B | 19.36M | 1.08% |
| Dec 31, 2018 | 1.79B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RPRX News
- 3 days ago - Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - GlobeNewsWire
- 15 days ago - Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - GlobeNewsWire
- 15 days ago - Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - GlobeNewsWire
- 15 days ago - Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 23 days ago - Royalty Pharma to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated - Seeking Alpha
- 6 weeks ago - Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript - Seeking Alpha